StorMagic Introduces the Most Cost-Effective HCI Solution for Edge and SMB Environments
11.6.2024 14:00:00 EEST | Business Wire | Press release
StorMagic®, solving the world’s edge data problems, today announced SvHCI, which combines a hypervisor and virtual networking with the provider’s proven virtual storage technology used by thousands of customers around the world. This full-stack HCI (hyperconverged infrastructure) solution is purpose-built for edge and small to medium-sized business (SMB) environments and includes StorMagic’s in-house 24x7x365 customer support.
According to the 2024 Gartner® Market Guide for Full-Stack Hyperconverged Infrastructure Software, “the 30% of the non-market leading full-stack HCI installed base that exists in 2024 will increase to 60% by 2029.”* StorMagic believes that this is validating the significant and growing appetite for this type of storage and compute architecture in the market in the wake of the significant market churn witnessed this year.
StorMagic’s SvSAN® is depended on for 100% uptime by customers who currently use VMware or Microsoft hypervisors and is the foundation of the new full-stack solution. SvHCI is a software solution that installs directly on new or existing servers and includes a KVM-based hypervisor, advanced virtual networking and SvSAN as the storage software layer. Just like SvSAN, StorMagic SvHCI simplifies operations and delivers high availability for edge and SMBs environments with only two servers, while lowering software costs by up to 62% over VMware.**
“StorMagic SvHCI delivers exactly what our customers and partners are telling us they need to run applications reliably at their edge and SMB sites,” said Dan Beer, chief executive officer, StorMagic. “This solution is founded on the same tried and true SvSAN code we have been delivering to customers for more than a decade with over 50,000 installations around the world. With SvHCI, we’re helping end users transition from costly, overengineered, overprovisioned software running on VMware to our purpose-built and dependable solution, saving them up to 62% on software costs alone.”
Pricing and Availability
Generally available later this summer, SvHCI is priced starting at $2,049 for a one-year subscription for a single server and up to 2 TB of storage. StorMagic has also launched today an SvHCI Global Beta Program through which customers and partners can get early access to the software and test on their own servers. To learn more about SvHCI and apply for the Global Beta Program, click here.
* Source: Gartner, Market Guide for Full-Stack Hyperconverged Infrastructure Software, By Jeffrey Hewitt, Philip Dawson, Julia Palmer, Tony Harvey, 8 April 2024.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
**Range of savings is 21% to 62%. Comparisons include SvHCI 1, 3 and 5 year subscription lengths plus maximum storage capacities of 2TB, 6TB, 12TB, 24TB and 48TB. VMware comparisons are for the same subscription length and storage capacity of VMware vSphere Foundation with VMware vSAN and VMware Cloud Foundation with VMware vSAN.
About StorMagic
StorMagic is solving the world’s edge data problems. We help organizations of all types and sizes use, protect and manage their applications and data at and near the edge. Our solutions are easy to implement and maintain, and eliminate downtime to provide value anytime, anywhere. StorMagic’s solutions are simple, reliable and cost-effective, without sacrificing enterprise-class features, for SMBs to Fortune 500 companies with one to thousands of sites.
Join the Conversation
Follow StorMagic on Facebook, Instagram, LinkedIn, and Twitter, and subscribe to our corporate blog and YouTube channel.
StorMagic, SvSAN, SvKMS and SvHCI are trademarks of StorMagic.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611750413/en/
Contacts
Matter Communications
stormagic@matternow.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom